SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging in community discussions as supporters rally behind recent ticker recovery and growing organic engagement. The community is actively pushing for a breakout, focusing on upcoming milestones and potential airdrops as they aim to establish the project within the broader meme coin ecosystem.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is currently surging as investors pivot toward the Base ecosystem, fueled by anticipation surrounding upcoming network events and a broader rotation of liquidity into decentralized exchanges. The community remains highly focused on the protocol's fee-generating utility and the long-term impact of its tokenomics model as traders position themselves for potential expansion in the coming cycles.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining traction as a high-conviction play within the Base ecosystem, with investors highlighting its unique link to AI-driven wealth and the narrative that Grok's own wallet holds the asset. The community is actively discussing the token's massive growth potential, often drawing comparisons to historical meme coin runs while emphasizing its status as an early-stage, under-the-radar opportunity.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following the announcement that SanDisk will replace it in the Nasdaq-100, fueling community debate about the long-term impact of AI on incumbent SaaS workflows and valuation. Investors are actively discussing the stock's sharp decline, weighing institutional de-risking and AI disruption fears against the company's deeply embedded enterprise utility and potential for future stabilization.

Global X Funds - Global X Silver Miners ETF

The Global X Silver Miners ETF (SIL) is drawing intense investor attention as silver prices reach historic highs, driven by a persistent supply deficit and strong industrial demand for the metal in AI, solar, and EV sectors. Market participants are actively debating the decoupling between silver's spot price and mining equities, with many looking for a dramatic catch-up rally in miners as the broader precious metals sector experiences increased volatility and record-breaking volume.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending as investors gear up for the anticipated April 13th topline data readout from the Phase 2/3 OptimUM-02 trial evaluating Darovasertib and Crizotinib in metastatic Uveal Melanoma. The community is heavily focused on whether the Progression-Free Survival and Overall Response Rate results will meet the high bar required for an Accelerated Approval filing, with sentiment bolstered by strong institutional interest and the company's robust balance sheet.

Byrna Technologies, Inc. is a less-lethal self-defense technology company, which engages in the business of developing, manufacturing, and selling innovative less-lethal personal security solutions. It operates through the following geographical segments: the United States, South Africa, Europe, South America, and Asia, and Canada. The company was founded on March 1, 2005 and is headquartered in Andover, MA.

Byrna Technologies Inc

Byrna Technologies is trending as investors respond to significant production increases and rising demand for its non-lethal self-defense devices, fueled by a broader market interest in security-focused stocks. The community remains deeply divided, with some highlighting strong fundamental growth and retail expansion, while others voice concerns over short-selling volatility and the company's long-term competitive position.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is facing intense scrutiny and shareholder frustration as investors actively discuss the company's discounted merger agreement with Garda Therapeutics and the perceived undervaluation of its core assets. The community is heavily focused on the potential to block the acquisition through legal injunctions or by organizing voting blocks, as many feel the tender offer fails to reflect the company's true value and cash position.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

Sei is experiencing renewed community focus as investors track its potential as a high-performance Layer-1 blockchain, with active discussions centering on upcoming network upgrades and its growing role in real-world asset tokenization. Traders are debating the project's long-term utility versus its recent price volatility, while many remain optimistic about its capacity to capture institutional interest and scale within the DeFi ecosystem.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401jK is gaining momentum as a community-driven project that uses memes to challenge the traditional retirement system and advocate for financial independence. The community is actively discussing its grassroots narrative, focusing on IRL raids and educational content while positioning the token as a rebellious alternative to corporate savings plans.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up

(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...

<ul class="summary-bullets"><li>Scynexis signed a definitive agreement to acquire SCY-770, a novel oral therapy to treat Autosomal Dominant Polycystic Kidney Disease.</li><li>The biotech firm will pay $8 million upfront to Poxel and up to another $8 million tied to development milestones.</li><li>The company plans to begin a Phase 2 study of SCY-770 in late 2026.</li></ul>Shares of Scynexis, Inc. (SCYX) gave up most of their early gains but traded around 2% higher in pre-market on Tuesday after the biotech firm announced a deal with Poxel S.A. to acquire a potential treatment for a kidney disease, alongside securing $40 million through a private placement.Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), a leading cause of kidney failure.Under the agreement, Scynexis will pay $8 million upfront and up to another $8 million tied to development milestones. The company could also pay up to $180 million in commercial milestones, including $125 million if annual sales reach $1 billion or more.<h2 class="st-heading-2">Scynexis To Begin Phase 2 Study Of SCY-770 In Late 2026</h2>The company plans to begin a Phase 2 study in late 2026, with early results expected in the second half of 2027. The therapy has also received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).The oral therapy is designed to target the root causes of ADPKD by slowing cyst growth and limiting disease progression.“SCY-770 is supported by a strong pre-clinical data package and a novel differentiated MOA that targets multiple key drivers of ADPKD progression, positioning it as a promising candidate in a significant rare disease market with a high unmet need. Our near-term priority is to efficiently advance SCY-770 into a Phase 2 POC study later this year,” said David Angulo, President and CEO of Scynexis.Separately, Scynexis said it expects to raise about $40 million upfront from the private placement, with the potential to bring in up to an additional $52.2 million if all warrants are exercised for cash.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SCYX">SCYX</a> on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said they want to see the company being bought out.<stembedurl>https://stocktwits.com/ViktorSinclair/message/649025612</stembedurl>Another user said the company should remain focused on the anti-fungal space.<stembedurl>https://stocktwits.com/Varus_q/message/649029010</stembedurl>Pre-market volumes were strong, with 7.8 million shares changing hands, compared with an average of around 0.4 million, according to Stocktwits data.Year-to-date, the stock has gained around 25%.For updates and corrections, email newsroom[at]stocktwits[dot]com

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

  Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market

The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.

Equity

SCYNEXIS Q4 Earnings Assessment

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

SCYX
Scynexis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SCYX News

SCYXScynexis Inc